Anti-angiogenic agents in metastatic colorectal cancer.

ABSTRACT: Colorectal cancer (CRC) is a major public health concern being the third leading cause of cancer mortality in the United States. The availability of better therapeutic options has led to a decline in cancer mortality in these patients. Surgical resection should be considered in all stages of the disease. The use of conversion therapy has made surgery a potentially curative option even in patients with initially unresectable metastatic disease. In this review we discuss the role of various anti-angiogenic agents in patients with metastatic CRC (mCRC). We describe the mechanism of action of these agents, and the rationale for their use in combination with chemotherapy. We also review important clinical studies that have evaluated the safety and efficacy of these agents in mCRC patients. Desp

SUBMITTER: Konda B 

PROVIDER: S-EPMC4501927 | biostudies-literature | 2015 Jul

REPOSITORIES: biostudies-literature